Association of gene polymorphisms with chronic kidney disease in high- or low-risk subjects defined by conventional risk factors

International Journal of Molecular Medicine

Volumn 23, Issue 6, 2009, Pages 785-792

  Yoshida, Tetsuro ^a   Kato, Kimihiko ^b   Yokoi, Kiyoshi ^b   Oguri, Mitsutoshi ^c   Watanabe, Sachiro ^d   Metoki, Norifumi ^e   Yoshida, Hidemi ^f   Satoh, Kei ^f   Aoyagi, Yukitoshi ^g   Nishigaki, Yutaka ^g   Nozawa, Yoshinori ^h   Yamada, Yoshiji ⁱ  

^a Inabe General Hospital   (Japan)

^b GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^d GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^e Hirosaki Stroke Center   (Japan)

^f HIROSAKI UNIVERSITY   (Japan)

^g TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^h GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

ⁱ MIE UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; End stage renal disease; Genetics; Polymorphism

Indexed keywords

ALANINE; APOLIPOPROTEIN E; ASPARAGINE; CD31 ANTIGEN; CHOLESTEROL ESTER TRANSFER PROTEIN; GENE PRODUCT; GLUTAMINE; GLYCINE; INTERSTITIAL COLLAGENASE; ISOLEUCINE; LEUCINE; LYSINE; PROTEIN COL3A1; PROTEIN PDE4D; PROTEIN SCAP; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

AGED; ANTIGENS, CD31; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL ESTER TRANSFER PROTEINS; COLLAGEN TYPE III; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY DISEASES; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RISK FACTORS;

EID: 67649562165     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000193     Document Type: Article

References (36)

1. Weiner DE, Tighiouart H, Amin MG, et al: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004.
2. Jafar TH, Stark PC, Schmid CH, et al: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003.
3. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ and Coresh J: Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 14: 2934-2941, 2003.
4. Ravera M, Re M, Deferrari L, Vettoretti S and Deferrari G: Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 17 (4 Suppl 2): 98-103, 2006.
5. Yamagata K, Ishida K, Sairenchi T, et al: Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 71: 159-166, 2007.
6. Iseki K: Chronic kidney disease in Japan from early predictions to current facts. Nephron Clin Pract 110: c268-c272, 2008.
7. Jee SH, Boulware LE, Guallar E, Suh I, Appel LJ and Miller ER III: Direct, progressive association of cardiovascular risk factors with incident proteinuria: results from the Korea Medical Insurance Corporation (KMIC) study. Arch Intern Med 165: 2299-2304, 2005.
8. Korstanje R and DiPetrillo K: Unraveling the genetics of chronic kidney disease using animal models. Am J Physiol Renal Physiol 287: F347-F352, 2004.
9. Perneger TV, Whelton PK and Klag MJ: Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors. Arch Intern Med 155: 1201-1208, 1995.
10. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1): 1-266, 2002.
11. Gharavi AG, Yan Y, Scolari F, et al: IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 26: 354-357, 2000.
12. Hanson RL, Craig DW and Millis MP: Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 56: 975-983, 2007.
13. Doi K, Noiri E, Nakao A, Fujita T, Kobayashi S and Tokunaga K: Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol 17: 823-830, 2006.
14. Wetmore JB, Hung AM, Lovett DH, Sen S, Quershy O and Johansen KL: Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney Int 68: 278-284, 2005.
15. Imai E, Matsuo S, Makino H, et al: Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 31: 1101-1107, 2008.
16. Go AS, Chertow GM, Fan D, McCulloch CE and Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
17. Itoh Y, Mizuki N, Shimada T, et al: High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 57: 717-729, 2005.
18. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
19. Pearce E, Tregouet DA, Samnegård A, et al: Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res 97: 1070-1076, 2005.
20. Armstrong C, Abilleira S, Sitzer M, Markus HS and Bevan S: Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke 38: 2895-2899, 2007.
21. Reeves WB and Andreoli TE: Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 97: 7667-7669, 2000.
22. Yang YL, Guh JY, Yang ML, et al: Interaction between high glucose and TGF-beta in cell cycle protein regulations in MDCK cells. J Am Soc Nephrol 9: 182-193, 1998.
23. Mathew S, Murty VV, Cheifetz S, George D, Massagué J and Chaganti RS: Transforming growth factor receptor gene TGFBR2 maps to human chromosome band 3p22. Genomics 20: 114-115, 1994.
24. Wong TY, Poon P, Chow KM, Szeto CC, Cheung MK and Li PK: Association of transforming growth factor-beta (TGF-beta) T869C (Leu10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney Int 63: 1831-1835, 2003.
25. Lambert JC, Brousseau T, Defosse V, et al: Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations - the ECTIM study. Hum Mol Genet 9: 57-61, 2000.
26. Hirashiki A, Yamada Y, Murase Y, et al: Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol 42: 1429-1437, 2003.
27. Thibaudin D, Thibaudin L, Berthoux P, et al: TNFA2 and d2 alleles of the tumor necrosis factor alpha gene polymorphism are associated with onset/occurrence of idiopathic membranous nephropathy. Kidney Int 71: 431-437, 2007.
28. Buraczynska M, Mierzicki P, Buraczynska K, Dragan M and Ksiazek A: Tumor necrosis factor-alpha gene polymorphism correlates with cardiovascular disease in patients with end-stage renal disease. Mol Diagn Ther 11: 257-263, 2007.
29. Yamada Y, Ichihara S, Izawa H, Tanaka M, et al: Genetic risk for coronary artery disease in individuals with or without type 2 diabetes. Mol Genet Metab 81: 282-290, 2004.
30. Yamada Y, Izawa H, Ichihara S, et al: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 347: 1916-1923, 2002.
31. Rundek T, Elkind MS, Pittman J, et al: Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 33: 1420-1423, 2002.
32. Sasaoka T, Kimura A, Hohta SA, Fukuda N, Kurosawa T and Izumi T: Polymorphisms in the platelet-endothelial cell adhesion molecule-1 (PECAM-1) gene, Asn563Ser and Gly670Arg, associated with myocardial infarction in the Japanese. Ann NY Acad Sci 947: 259-269, 2001.
33. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G and Tybjaerg-Hansen A: Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101: 1907-1912, 2000.
34. Pepin M, Schwarze U, Superti-Furga A and Byers PH: Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 342: 673-680, 2000.
35. Fiegenbaum M, Silveira FR, Van der Sand CR, et al: Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J 5: 359-364, 2005.
36. Brophy VH, Ro SK, Rhees BK, et al: Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status. Stroke 37: 1385-1390, 2006.